127. Frontotemporal lobar degeneration Clinical trials / Disease details
Clinical trials : 89 / Drugs : 104 - (DrugBank : 33) / Drug target genes : 40 - Drug target pathways : 117
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05184569 (ClinicalTrials.gov) | January 20, 2022 | 17/12/2021 | Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology | Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology | Semantic Dementia | Drug: Verdiperstat | Peter Ljubenkov, MD | National Institutes of Health (NIH);Alzheimer's Association;National Institute on Aging (NIA) | Not yet recruiting | 18 Years | 85 Years | All | 64 | Phase 1 | NULL |